Phreesia, Inc. (NYSE:PHR) Given Average Recommendation of "Buy" by Brokerages

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven research firms that are currently covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $31.64.

PHR has been the subject of several research analyst reports. DA Davidson cut their target price on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, April 14th. KeyCorp cut their price objective on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Citigroup reissued a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Canaccord Genuity Group cut their price target on Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th. Finally, Truist Financial raised their price objective on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th.

Insider Buying and Selling

In other Phreesia news, Director Michael Weintraub sold 2,569 shares of the company's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $27.86, for a total transaction of $71,572.34. Following the sale, the director now directly owns 143,039 shares of the company's stock, valued at approximately $3,985,066.54. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Allison C. Hoffman sold 3,496 shares of Phreesia stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $25.32, for a total transaction of $88,518.72. Following the completion of the transaction, the general counsel now owns 139,134 shares of the company's stock, valued at $3,522,872.88. This trade represents a 2.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,056 shares of company stock worth $1,315,504 in the last 90 days. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Phreesia

A number of institutional investors and hedge funds have recently bought and sold shares of PHR. Rhumbline Advisers raised its holdings in shares of Phreesia by 3.8% in the first quarter. Rhumbline Advisers now owns 86,844 shares of the company's stock valued at $2,220,000 after buying an additional 3,213 shares during the last quarter. Strs Ohio bought a new position in shares of Phreesia in the first quarter worth about $271,000. Acadian Asset Management LLC lifted its position in shares of Phreesia by 105.2% during the first quarter. Acadian Asset Management LLC now owns 225,317 shares of the company's stock worth $5,754,000 after purchasing an additional 115,527 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Phreesia by 108.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after purchasing an additional 1,377,904 shares during the last quarter. Finally, Caxton Associates LLP acquired a new stake in shares of Phreesia in the first quarter valued at approximately $316,000. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Trading Down 2.4%

NYSE:PHR opened at $25.99 on Friday. The company's 50 day moving average is $25.01 and its 200-day moving average is $25.77. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia has a 12 month low of $17.07 and a 12 month high of $30.53. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -17.68 and a beta of 0.68.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter last year, the firm posted ($0.05) EPS. The business's quarterly revenue was up 14.5% on a year-over-year basis. Equities analysts anticipate that Phreesia will post -1.1 EPS for the current year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.